Correspondence 0001104659-23-055096 from Y-mAbs Therapeutics, Inc. (YMAB) (CIK 0001722964)
Y-mAbs Therapeutics, Inc. (YMAB) (CIK 0001722964)
Date: May 2, 2023 · CIK: 0001722964 · Accession: 0001104659-23-055096
AI Filing Summary & Sentiment
File numbers found in text: 333-271006
Letter
Y-mAbs Therapeutics, Inc.
230 Park Avenue, Suite 3350
New York, NY 10169
May 2, 2023
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Daniel Crawford
Re: Y-mAbs Therapeutics, Inc.
Registration Statement on Form S-3 (File No. 333-271006)
Request for Acceleration of Effective Date
Mr. Crawford:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-271006) (the “Registration Statement”) to become effective on May 5, 2023, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Sarah Sellers of Cooley LLP, counsel to the Registrant, at (212) 479-6370, or in her absence, Divakar Gupta at (212) 479-6474.
[Signature page follows]
Very truly yours,
Y-mAbs
Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Y-mAbs
Therapeutics, Inc.
230 Park Avenue, Suite 3350
New York, NY 10169
May 2, 2023
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Daniel Crawford
Re: Y-mAbs Therapeutics, Inc.
Registration Statement on Form S-3 (File
No. 333-271006)
Request for Acceleration of Effective Date
Mr. Crawford:
In accordance with Rule 461 under the Securities Act of 1933,
as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission
take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-271006) (the “Registration
Statement”) to become effective on May 5, 2023, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please
orally confirm that event with Sarah Sellers of Cooley LLP, counsel to the Registrant, at (212) 479-6370, or in her absence, Divakar
Gupta at (212) 479-6474.
[Signature page follows]
Very truly yours,
Y-mAbs
Therapeutics, Inc.
By: /s/ Thomas Gad
Thomas Gad
Founder, President, Interim Chief Executive
Officer and Head of Business Development
cc:
Sune R. Nyland, Y-mAbs Therapeutics, Inc.
Bo Kruse, Y-mAbs Therapeutics, Inc.
Sarah Sellers, Cooley LLP
Divakar Gupta, Cooley LLP
Signature Page to Company Acceleration
Request – S-3